true
{{custommediabasic::headline_all_caps}}
{{custommediabasic::headline_less_padding_bottom}}
#BF0D3E
#02253E
#02253E
30px 0 30px 0
https://www.galliprantvet.com/us/en/how-it-works
/uploads/flowchart_v5-63fa7ce8f4de3b5ca1bdcfbdbf32e399.jpg
{{custommediabasic::logo_alt_text}}
550
true
https://www.galliprantvet.com/us/en/how-it-works
/uploads/header-b71b5f5d95411d6ab54f53eb9cdb3941.jpg
{{custommediabasic::header_image_alt_text}}
{black}Go with Galliprant® (grapiprant tablets) for the Moments that Matter
{{custommediabasic::headline_smaller}}
{{custommediabasic::subhead}}
{{custommediabasic::subhead_url}}
true
{{custommediabasic::headline_subhead_below_header_image}}
When it comes to canine osteoarthritis (OA) pain medications, Galliprant works differently and can help protect the moments that matter between your patients and their owners.
Unlike traditional NSAIDS Galliprant controls PGE2-elicited pain and inflammation by selectively antagonizing the EP4 receptor, reducing the severity of pain and how much pain interferes with daily activities.
#02253E
true
true
true
{{custommediabasic::cta_callout_secondary}}
https://www.galliprantvet.com/us/en/how-it-works
{{custommediabasic::cta}}
HOW GALLIPRANT WORKS
true
It’s a first-in-class non-COX inhibiting NSAID1 that targets canine OA pain and inflammation while reducing the impact on GI, kidney and liver homeostasis.1,2ǂ
Prescribe Galliprant as your go-to NSAID for canine OA.
ǂ Monitoring is recommended if used long-term
true
{{custommediabasic::pre_footer_center}}
{{custommediabasic::pre_footer_larger}}
Indication
Galliprant is an NSAID{sup}1{/sup} that controls pain and inflammation associated with osteoarthritis in dogs.
Important Safety Information
Not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. Do not use in dogs that have a hypersensitivity to grapiprant. If Galliprant is used long term, appropriate monitoring is recommended. Concomitant use of Galliprant with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy. Click here for full prescribing information.
References
1 Kirkby Shaw K, Rausch-Derra LC, Rhodes L. Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation. Vet Med Sci. 2016;2:3-9.
PM-US-20-1626
2 Rausch-Derra L, Huebner M, Rhodes L. Evaluation of the safety of long-term, daily oral administration of grapiprant, a novel drug for treatment of osteoarthritis pain and inflammation, in healthy dogs. Am J Vet Res. 2015;76:853-9.
©2020 Elanco or its affiliates. Elanco, Galliprant and the diagonal bar logo are trademarks of Elanco or its affiliates.
